 Vascular Biogenics Ltd NASDAQ: VBLT shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet the primary endpoints. Vascular Biogenics said the trial did not achieve a. 